Sage Therapeutics, Inc. (NASDAQ:SAGE) to Post Q1 2024 Earnings of ($1.64) Per Share, Leerink Partnrs Forecasts
The Cerbat Gem -

Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Analysts at Leerink Partnrs increased their Q1 2024 earnings estimates for shares of Sage Therapeutics in a research report issued on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn ($1.64) per share for the quarter, up from their previous […]

In related news